证券代码：688161 证券简称：威高骨科 公告编号：2025-046 山东威高骨科材料股份有限公司 关于变更部分募投项目暨收购苏州杰思拜尔医疗科技 有限公司股权并对其增资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 新项目在实施过程中可能会受到产业政策变化、技术趋势变化、市场环 境变化等因素的影响，会使项目进度与预测出现差异，最终可能导致项目无 法按时完成，经济收益不达预期的风险。 2、技术风险 杰思拜尔的在研产品需要进一步的资金投入和研发创新，新一代产品的 山东威高骨科材料股份有限公司（以下简称"公司"或"威高骨科"）拟变 更"研发中心建设项目"（拟投入金额 37,962.55 万元）中未使用的部分募 集资金 8,646 万元，用于收购苏州杰思拜尔医疗科技有限公司（以下简称"杰 思拜尔"或"标的公司"）部分股权并对杰思拜尔增资，交易完成后，公司 持有杰思拜尔 55%股权，并将其纳入合并报表范围；"研发中心建设项目" 剩余募集资金将继续用于该募投项目建设。 公司拟使用募集资金收购杰思拜尔股权并对杰思 ...

证券代码：688161 证券简称：威高骨科 公告编号：2025-048 山东威高骨科材料股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第三次临时股东会 召开日期时间：2025 年 12 月 29 日 14 点 50 分 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 29 日 至2025 年 12 月 29 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 股东会召开日期：2025年12月29日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三 ...

山东威高骨科材料股份有限公司 第三届董事会第十七次会议决议公告 证券代码：688161 证券简称：威高骨科 公告编号：2025-049 山东威高骨科材料股份有限公司（以下简称"公司"）第三届董事会第十七 次会议于 2025 年 12 月 10 日以现场及通讯相结合的方式召开。本次会议应出席 董事 8 人，实际出席董事 8 人，会议由董事长陈敏女士主持，本次董事会会议的 召集和召开程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定，会议决议合法、有效。 二、董事会会议审议情况 1、审议通过《关于变更部分募投项目暨收购苏州杰思拜尔医疗科技有限公 司股权并对其增资的议案》 公司董事会认为：本次变更事项符合相关法律法规的要求，收购杰思拜尔部 分股权并对其增资满足公司战略发展方向，能够扩展公司骨科微创细分领域产品 竞争力，促进公司持续发展。 表决结果：8 票同意，0 票反对，0 票弃权。 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）披露的《关于 变更部分募投项目暨收购苏州杰思拜尔医疗科技有限公司股权并对其增资的公 告》（公告编号：2025-046）。 2、审议通过《关于补选公 ...

格隆汇12月11日丨威高骨科(688161.SH)公布，公司拟变更"研发中心建设项目"（拟投入金额37,962.55 万元）中未使用的部分募集资金8,646万元，用于收购苏州杰思拜尔医疗科技有限公司（以下简称"杰思 拜尔"或"标的公司"）部分股权并对杰思拜尔增资，交易完成后，公司持有杰思拜尔55%股权，并将其 纳入合并报表范围；"研发中心建设项目"剩余募集资金将继续用于该募投项目建设。 杰思拜尔专注于脊柱微创和运动医学领域，拥有骨科微创和有源能量设备两大技术平台，主要产品包括 经皮脊柱内窥镜、骨科关节内窥镜、超声骨刀、医用内窥镜摄像系统、高频电刀及各类配套器械耗材产 品，在骨科微创产品和有源能量产品两大产品领域拥有较强的研发实力。 ...

截至发稿，威高骨科市值为112亿元。 每经头条（nbdtoutiao）——白金信用卡权益大缩水：贵宾厅限次、酒店减量⋯⋯银行吐槽没赚头，"羊 毛党"薅了个寂寞 每经AI快讯，威高骨科（SH 688161，收盘价：28.08元）12月11日晚间发布公告称，公司第三届第十七 次董事会会议于2025年12月10日以现场及通讯相结合的方式召开。会议审议了《关于提请召开公司2025 年第三次临时股东会的议案》等文件。 2024年1至12月份，威高骨科的营业收入构成为：医疗器械制造行业占比99.85%，其他业务占比 0.15%。 （记者 曾健辉） ...

威高骨科12月11日公告，公司董事会于2025年12月10日召开了第三届董事会第十七次会议，审议通过了 《关于补选公司第三届董事会非独立董事及聘任公司总经理的议案》，同意提名李进取为第三届董事会 非独立董事候选人，其任期自公司股东会审议通过之日起至第三届董事会任期届满之日止。同意聘任李 进取为公司总经理，自本次董事会审议通过之日起至第三届董事会任期届满为止。 ...

Group 1 - The Sci-Tech 50 Index opened lower on November 26 but later rose significantly, closing at 1315.04 points with a gain of 0.99% and a trading volume of approximately 57.58 billion yuan [1] - The Sci-Tech Comprehensive Index also increased by 0.83%, closing at 1560.57 points with a total trading volume of about 182.8 billion yuan [2] - Excluding suspended stocks, the remaining 589 stocks on the Sci-Tech board showed an average decline of 0.15% with an average turnover rate of 2.66% [2] Group 2 - Semiconductor and biopharmaceutical stocks were notably active, while aviation and software service stocks experienced the largest declines [2] - Individual stock performance included Mingwei Electronics, Changguang Huaxin, Jindike, and Dongxin Co., which all hit the daily limit up, while Kangwei Century saw the largest drop at 10.78% [2] - In terms of trading volume, Hanwujing led with 11.89 billion yuan, while ST Guandian had the lowest at 1.027 million yuan [2] Group 3 - The turnover rate for Aerospace Huanyu was the highest at 31.51%, while Weigao Orthopedics had the lowest at 0.18% [3]

Core Viewpoint - On November 21, Weigao Orthopedics experienced a decline of 3.62% in stock price, with a trading volume of 48.15 million yuan, indicating potential market volatility and investor sentiment concerns [1]. Financing Summary - On the same day, Weigao Orthopedics had a financing buy-in amount of 9.15 million yuan and a financing repayment of 15.83 million yuan, resulting in a net financing outflow of 6.68 million yuan [1]. - The total financing and securities balance as of November 21 is 142 million yuan, which accounts for 1.25% of the circulating market value, indicating a high level of financing activity compared to the past year [1]. - The company had no shares repaid in securities lending on November 21, with 300 shares sold short, amounting to 8,541 yuan at the closing price, and a securities lending balance of 15.23 million yuan, also at a high level compared to the past year [1]. Financial Performance - For the period from January to September 2025, Weigao Orthopedics reported a revenue of 1.11 billion yuan, reflecting a year-on-year growth of 2.12%, while the net profit attributable to shareholders was 207 million yuan, showing a significant increase of 26.24% [2]. - The company has distributed a total of 575 million yuan in dividends since its A-share listing, with 367 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Weigao Orthopedics reached 10,700, an increase of 18.33% from the previous period, while the average circulating shares per person decreased by 15.49% to 37,418 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest, holding 3.44 million shares, an increase of 392,000 shares from the previous period, while Penghua Medical Technology Stock A is a new entrant as the tenth largest shareholder with 1.10 million shares [3].

Core Insights - The 24th Chinese Orthopaedic Association (COA) conference showcased significant advancements in orthopedic technology, emphasizing the integration of robotics, navigation, imaging, and biomaterials under the theme "Digital Intelligence in Orthopedics" [2] - The conference attracted 20,188 registered participants and received 37,222 submissions, indicating a strong interest in orthopedic innovations [2] Group 1: Robotics and Navigation Systems - Surgical robots and navigation systems are expanding across various orthopedic fields, moving beyond joint surgeries to include spine, trauma, and sports medicine, focusing on precision and standardization [4] - Companies like Stryker, Tianzhihang, and others are presenting comprehensive orthopedic platforms that integrate imaging, navigation, and robotic arms, forming a closed-loop system for enhanced surgical outcomes [4] - The Trinity system by Tuo Dao Medical demonstrates a unified platform for rapid switching between surgical procedures, showcasing advancements in AI planning and real-time navigation [19] Group 2: Biomaterials and Bone Repair - The competition in bone repair and biomaterials is intensifying, with companies offering innovative solutions such as absorbable screws and 3D-printed bioceramics, focusing on osteogenic activity and infection resistance [4] - Smartbone and other manufacturers are introducing advanced materials that not only fill defects but also promote bone regeneration and integration [4] Group 3: Domestic Innovations - Domestic companies are accelerating the development of high-end joint prosthetics and key materials, with a focus on integrating materials, prosthetic design, and manufacturing processes [4] - The collaboration between local firms and international companies is shifting from product showcases to establishing standards and ecosystems, enhancing the overall orthopedic landscape [4] Group 4: Key Product Launches - Stryker highlighted its latest products, including the Mako robotic system, which integrates multiple surgical techniques for hip and knee replacements, enhancing precision and efficiency [5][7] - Rosenboht signed a strategic partnership with the Chinese University of Hong Kong to advance intelligent surgical technologies, aiming for more precise and minimally invasive orthopedic procedures [12][14] - The launch of the "Panshi Self-Pressing 3D Partition Bone Trabecular Biological Knee Prosthesis" by Jiashite Medical showcases advancements in mechanical stability and biological fixation [40][42] Group 5: Technological Integration - Companies are increasingly focusing on integrating AI and imaging technologies to enhance surgical precision and safety, as seen in the solutions presented by Meiya Optical and other firms [46][50] - The introduction of AR navigation systems by Linyan Medical represents a significant technological advancement, improving the visibility and accuracy of spinal surgeries [53][55] Group 6: Comprehensive Solutions - The conference highlighted the importance of comprehensive solutions that encompass preoperative planning, intraoperative guidance, and postoperative evaluation, as demonstrated by various exhibitors [4][60] - Companies like Weigao and others are showcasing integrated solutions that leverage digital technologies to enhance the entire orthopedic treatment process [100][102]

近日，威高骨科发布公告称，公司董事、总经理卢均强因工作调整辞去公司第三届董事会董事及总经理 职务。副总经理李进取将代行总经理职责，直至董事会选聘新任总经理。卢均强辞职后，将继续在公司 控股股东、实际控制人控制的企业内任职。 截至本公告披露日，卢均强先生通过威海弘阳瑞信息技术中心（有限合伙）持有公司0.10%的股份。卢 均强辞去公司董事和高管职务后，将继续严格遵守《上海证券交易所科创板股票上市规则》《上市公司 股东减持股份管理暂行办法》《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》等规 定及其所作的相关承诺。 (编辑：杨燕 林辰)关键字： 医疗 （威高骨科公告） ...